Analyst Samantha Semenkow Maintains Bullish Rating on Spyre Therapeutics
Analyst Samantha Semenkow has reaffirmed a bullish rating on Spyre Therapeutics, maintaining a price target of $119.
Stocks · News reference
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120
UBS analyst Alice Nettleton initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $120.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Spyre Therapeutics shares are trading higher after BTIG reiterated its Buy rating on the stock and maintained a $121 price target.
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
Reported Sunday, Spyre Shows Anti-α4β7, Anti-TL1A And Anti-IL-23 Antibodies Each Efficacious In Humanized Mouse Colitis Model, With Combinations Further Improving Efficacy, At UEGW 2026